Fadi Haddad, MD, MD Anderson Cancer Center, Houston, TX, comments on the results of a study investigating the factors associated with a successful treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) who have discontinued treatment with imatinib, dasatinib, and nilotinib. The study revealed that a deep molecular response rate of four (MR4) or MR4.5 for five years or longer is the most important indicator for successful TFR. In addition, the study showed that the type of frontline TKI or the reason for treatment discontinuation did not impact TFR. Lastly, the study reported that patients who relapsed after treatment discontinuation were able to regain a deep molecular response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть